Zincovery, a pioneering New Zealand-based startup, has successfully raised $9 million in funding to advance its innovative technology aimed at transforming the zinc recycling industry. Each year, over 10 million tonnes of hazardous dust waste are generated from the steel recycling sector, containing a staggering $10 billion worth of zinc. Unfortunately, a significant portion of this valuable resource ends up in landfills, while existing recycling methods are notably expensive and carbon-intensive, producing zinc with twice the CO2 footprint of mined alternatives. With this fresh capital infusion, Zincovery is poised to tackle these pressing issues by further developing its environmentally friendly technology, designed to efficiently extract and recycle zinc, minimizing waste and reducing greenhouse gas emissions. The funding will support the scaling of Zincovery’s operations, allowing the company to refine its processes, expand its research and development efforts, and initiate pilot projects that demonstrate the viability of its groundbreaking approach. As the world increasingly prioritizes sustainability, Zincovery stands at the forefront of a crucial shift in the recycling industry, offering a path toward a more efficient and eco-conscious future for zinc recovery. With this funding, Zincovery aims not only to reclaim valuable resources but also to contribute meaningfully to global efforts in reducing industrial waste and minimizing environmental impact, setting a new standard for the steel recycling sector and beyond.
Zincovery Secures $9 Million in Funding to Transform Zinc Recycling Industry
Get the full Zincovery company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Handle.com
Fortune 500 material suppliers and contractors trust Handle software on a daily basis to provide their credit and finance departments with an end-to-end solution. Purpose-built for material suppliers and equipment dealers to manage the entire process of online payments and lien management.
$27.0M Series b
today
Texas Automated Robotics Systems, LLC
Tars Robotics, based in Houston Texas, strives to equip manufacturers with the highest quality robotic automation equipment at the most economical value in the industry. Our goal is to enable as many American manufacturers with the ability to compete in the global injection molding industry. We continue to support the initiative to re-shore products from all industries back to the United States. We offer a wide and unique line of robotic arms for machines ranging from 30 tons to 4,000 tons while providing the best solutions no matter how intelligible or complex. With our customer’s need in mind, our product lines include a diverse series of robots designed for sprue and parts removal, insert molding, de-gating, in-mold labeling, and parts stacking.
$513.0M Seed
today
Viseur AI - Digital Pathology Platform
Viseur AI is a digital pathology and medical imaging platform built to become the operating system of AI-enabled diagnostics. We unify Pathology Information Management (PIMS), Digital Pathology / WSI viewing (IMS), AI model deployment and governance, and enterprise-grade integrations into a single, vendor-agnostic platform designed for real clinical workflows. Healthcare systems and diagnostic labs struggle with fragmented pathology workflows, scanner-locked software, and AI solutions that rarely reach routine clinical use. Viseur AI addresses this by delivering an end-to-end digital pathology platform from specimen to report, combining enterprise-grade WSI viewing, AI model deployment and management, on-prem or hybrid architectures aligned with data privacy and regulatory requirements, and deep LIS, HIS, and PACS integrations that enable standardised and scalable operations across multiple sites. Certified under ISO 13485, ISO 27001, and ISO/IEC 15504-SPICE, Viseur AI creates a foundation for clear and compatible AI in healthcare.
$350.0K Seed
today
Imperagen
Imperagen is advancing enzyme engineering through an integrated, AI-driven platform that enables faster and more precise development of high-performance enzymes. By combining advanced computational modeling with automated lab testing, we help companies improve production processes while reducing cost, time, and environmental impact. Founded by researchers from the Manchester Institute of Biotechnology, Imperagen brings together expertise in physics-based simulation, machine learning, and high-throughput experimentation. Our closed-loop platform continuously learns from real-world data, allowing us to design, test, and refine enzymes with greater accuracy and efficiency than traditional approaches . We take a problem-specific approach, tailoring each solution to the unique requirements of a given enzyme, reaction, and application. We work with organizations across pharma, life sciences, chemicals, food, and consumer goods to solve complex enzyme engineering challenges. Our approach helps reduce development risk, shorten timelines, and support the shift toward more sustainable, enzyme-based manufacturing. Get in touch to learn more about our innovative platform and discover how we can quickly transform your enzyme needs into market-ready solutions.
$6.4M Seed
today
Omni
Omni is an AI analytics platform that empowers everyone—regardless of technical ability—to easily analyze data using AI, spreadsheets, SQL, or point-and-click interfaces. It is built on a semantic layer that makes sure every insight is accurate and dependable. Beyond powering internal analytics, Omni makes it easy for businesses to offer highly customizable in-product analytics to their customers.
$120.0M Series c
today